Abstract
Purpose of Review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. Recent Findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 188-192 |
| Number of pages | 5 |
| Journal | Current Opinion in Gastroenterology |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2012 |
Keywords
- boceprevir
- direct-acting antivirals
- hepatitis C virus
- protease inhibitor
- telaprevir
ASJC Scopus subject areas
- Gastroenterology